Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 247

1.

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.

Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q.

Nat Commun. 2019 Jun 6;10(1):2484. doi: 10.1038/s41467-019-10127-x.

2.

Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis.

Soekojo CY, Wang GM, Chen Y, Casan J, Wolyncewicz G, Lin A, Poon LM, de Mel S, Koh LP, Tan LK, Ooi MG, Nagarajan C, Liu Y, Lai YY, Huang XJ, Spencer A, Gopalakrishnan SK, Lu J, Chng WJ.

Clin Lymphoma Myeloma Leuk. 2019 Apr 28. pii: S2152-2650(19)30143-0. doi: 10.1016/j.clml.2019.04.011. [Epub ahead of print]

PMID:
31171473
3.

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.

Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M.

Clin Lymphoma Myeloma Leuk. 2019 May 2. pii: S2152-2650(19)30028-X. doi: 10.1016/j.clml.2019.04.018. [Epub ahead of print]

PMID:
31160237
4.

STAT3: A Promising Therapeutic Target in Multiple Myeloma.

Chong PSY, Chng WJ, de Mel S.

Cancers (Basel). 2019 May 26;11(5). pii: E731. doi: 10.3390/cancers11050731. Review.

5.

Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact.

Li Z, Wong KY, Calin GA, Chng WJ, Chan GC, Chim CS.

Clin Epigenetics. 2019 May 7;11(1):71. doi: 10.1186/s13148-019-0669-2.

6.

Molecular pathogenic pathways in extranodal NK/T cell lymphoma.

de Mel S, Hue SS, Jeyasekharan AD, Chng WJ, Ng SB.

J Hematol Oncol. 2019 Apr 2;12(1):33. doi: 10.1186/s13045-019-0716-7. Review.

7.

Cancer in 2019 - Progress and Challenges - A Perspective.

Chng WJ.

Ann Acad Med Singapore. 2019 Feb;48(2):45-47. No abstract available.

8.

Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries.

Hungria VTM, Lee JH, Maiolino A, de Queiroz Crusoe E, Martinez G, Bittencourt R, Duarte GO, Fantl DB, Navarro JR, Conte G, Gomez-Almaguer D, Ruiz-Argüelles GJ, Kim K, Shimizu K, Chen W, Huang SY, Chng WJ, Chim CS, Nawarawong W, Durie B.

Ann Hematol. 2019 Apr;98(4):941-949. doi: 10.1007/s00277-019-03602-4. Epub 2019 Feb 6.

PMID:
30729281
9.

Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders.

de Mel S, Tan JZ, Jeyasekharan AD, Chng WJ, Ng SB.

Front Pediatr. 2019 Jan 17;6:405. doi: 10.3389/fped.2018.00405. eCollection 2018. Review.

10.

Towards understanding of PRC2 binding to RNA.

Yan J, Dutta B, Hee YT, Chng WJ.

RNA Biol. 2019 Feb;16(2):176-184. doi: 10.1080/15476286.2019.1565283. Epub 2019 Jan 8. Review.

PMID:
30608221
11.

Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.

Lim SL, Damnernsawad A, Shyamsunder P, Chng WJ, Han BC, Xu L, Pan J, Pravin DP, Alkan S, Tyner JW, Koeffler HP.

Haematologica. 2019 Jun;104(6):1209-1220. doi: 10.3324/haematol.2018.201483. Epub 2019 Jan 3.

12.

Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres.

Chan EHL, De-Silva D, Lin AHF, Rabin N, Wechalekar A, Popat R, Chng WJ, Yong KL.

Br J Haematol. 2018 Dec 28. doi: 10.1111/bjh.15743. [Epub ahead of print] No abstract available.

PMID:
30592025
13.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.

Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10.

PMID:
30545780
14.

MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.

Xie Z, Chooi JY, Toh SHM, Yang D, Basri NB, Ho YS, Chng WJ.

Leukemia. 2019 Mar;33(3):739-748. doi: 10.1038/s41375-018-0300-0. Epub 2018 Nov 23.

PMID:
30470837
15.

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.

Rassidakis GZ, Herold N, Myrberg IH, Tsesmetzis N, Rudd SG, Henter JI, Schaller T, Ng SB, Chng WJ, Yan B, Ng CH, Ravandi F, Andreeff M, Kantarjian HM, Medeiros LJ, Xagoraris I, Khoury JD.

Blood Cancer J. 2018 Oct 19;8(11):98. doi: 10.1038/s41408-018-0134-z.

16.

Non-canonical activation of β-catenin by PRL-3 phosphatase in acute myeloid leukemia.

Chong PSY, Zhou J, Chooi JY, Chan ZL, Toh SHM, Tan TZ, Wee S, Gunaratne J, Zeng Q, Chng WJ.

Oncogene. 2019 Feb;38(9):1508-1519. doi: 10.1038/s41388-018-0526-3. Epub 2018 Oct 10.

PMID:
30305722
17.

Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies.

Zhou J, Chng WJ.

World J Clin Oncol. 2018 Sep 14;9(5):90-97. doi: 10.5306/wjco.v9.i5.90. Review.

18.

Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.

Chu-Farseeva YY, Mustafa N, Poulsen A, Tan EC, Yen JJY, Chng WJ, Dymock BW.

Eur J Med Chem. 2018 Oct 5;158:593-619. doi: 10.1016/j.ejmech.2018.09.024. Epub 2018 Sep 11.

PMID:
30243158
19.

The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies.

Arora L, Kumar AP, Arfuso F, Chng WJ, Sethi G.

Cancers (Basel). 2018 Sep 13;10(9). pii: E327. doi: 10.3390/cancers10090327. Review.

20.

LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL).

Hee YT, Yan J, Nizetic D, Chng WJ.

Oncotarget. 2018 Aug 7;9(61):31832-31841. doi: 10.18632/oncotarget.25835. eCollection 2018 Aug 7.

21.

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Luchtel RA, Dasari S, Oishi N, Pedersen MB, Hu G, Rech KL, Ketterling RP, Sidhu J, Wang X, Katoh R, Dogan A, Kip NS, Cunningham JM, Sun Z, Baheti S, Porcher JC, Said JW, Jiang L, Hamilton-Dutoit SJ, Møller MB, Nørgaard P, Bennani NN, Chng WJ, Huang G, Link BK, Facchetti F, Cerhan JR, d'Amore F, Ansell SM, Feldman AL.

Blood. 2018 Sep 27;132(13):1386-1398. doi: 10.1182/blood-2018-03-838524. Epub 2018 Aug 9.

PMID:
30093402
22.

Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).

Rashid MBMA, Toh TB, Hooi L, Silva A, Zhang Y, Tan PF, Teh AL, Karnani N, Jha S, Ho CM, Chng WJ, Ho D, Chow EK.

Sci Transl Med. 2018 Aug 8;10(453). pii: eaan0941. doi: 10.1126/scitranslmed.aan0941.

PMID:
30089632
23.

ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia.

Zhou J, Ng Y, Chng WJ.

Cell Mol Life Sci. 2018 Nov;75(21):3931-3941. doi: 10.1007/s00018-018-2895-8. Epub 2018 Jul 31. Review.

PMID:
30066088
24.

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis.

Teoh PJ, An O, Chung TH, Chooi JY, Toh SHM, Fan S, Wang W, Koh BTH, Fullwood MJ, Ooi MG, de Mel S, Soekojo CY, Chen L, Ng SB, Yang H, Chng WJ.

Blood. 2018 Sep 20;132(12):1304-1317. doi: 10.1182/blood-2018-02-832576. Epub 2018 Jul 30.

PMID:
30061158
25.

Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.

Song TL, Nairismägi ML, Laurensia Y, Lim JQ, Tan J, Li ZM, Pang WL, Kizhakeyil A, Wijaya GC, Huang DC, Nagarajan S, Chia BK, Cheah D, Liu YH, Zhang F, Rao HL, Tang T, Wong EK, Bei JX, Iqbal J, Grigoropoulos NF, Ng SB, Chng WJ, Teh BT, Tan SY, Verma NK, Fan H, Lim ST, Ong CK.

Blood. 2018 Sep 13;132(11):1146-1158. doi: 10.1182/blood-2018-01-829424. Epub 2018 Jul 27.

26.

BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia.

Zhou Y, Zhou J, Lu X, Tan TZ, Chng WJ.

BMC Cancer. 2018 Jul 11;18(1):731. doi: 10.1186/s12885-018-4661-6.

27.

The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation.

de Mel S, Soon GS, Mok Y, Chung TH, Jeyasekharan AD, Chng WJ, Ng SB.

Int J Mol Sci. 2018 Jun 30;19(7). pii: E1931. doi: 10.3390/ijms19071931. Review.

28.

Potential Clinical Application of Genomics in Multiple Myeloma.

Soekojo CY, de Mel S, Ooi M, Yan B, Chng WJ.

Int J Mol Sci. 2018 Jun 10;19(6). pii: E1721. doi: 10.3390/ijms19061721. Review.

29.

Preleukemic and second-hit mutational events in an acute myeloid leukemia patient with a novel germline RUNX1 mutation.

Ng IK, Lee J, Ng C, Kosmo B, Chiu L, Seah E, Mok MMH, Tan K, Osato M, Chng WJ, Yan B, Tan LK.

Biomark Res. 2018 May 11;6:16. doi: 10.1186/s40364-018-0130-2. eCollection 2018.

30.

Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma.

Shanmugam MK, Ahn KS, Lee JH, Kannaiyan R, Mustafa N, Manu KA, Siveen KS, Sethi G, Chng WJ, Kumar AP.

Front Pharmacol. 2018 May 3;9:365. doi: 10.3389/fphar.2018.00365. eCollection 2018.

31.

Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.

Khoo AL, Zhao YJ, Teng M, Ying D, Jin J, Chee YL, Poon LM, Lim SE, Koh LP, Chng WJ, Lim BP, Hsu LY, Chai LYA.

Int J Antimicrob Agents. 2018 Sep;52(3):350-357. doi: 10.1016/j.ijantimicag.2018.04.017. Epub 2018 May 9.

PMID:
29751120
32.

Universal monitoring of minimal residual disease in acute myeloid leukemia.

Coustan-Smith E, Song G, Shurtleff S, Yeoh AE, Chng WJ, Chen SP, Rubnitz JE, Pui CH, Downing JR, Campana D.

JCI Insight. 2018 May 3;3(9). pii: 98561. doi: 10.1172/jci.insight.98561.

33.

NF-κB promotes the stem-like properties of leukemia cells by activation of LIN28B.

Zhou J, Chooi JY, Ching YQ, Quah JY, Toh SH, Ng Y, Tan TZ, Chng WJ.

World J Stem Cells. 2018 Apr 26;10(4):34-42. doi: 10.4252/wjsc.v10.i4.34.

34.

Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma.

de Mel S, Chen Y, Lin A, Soh TG, Ooi M, Yap ES, Donato LKS, Halim NAA, Mah J, Lim K, Poon LM, Tan B, Yelly, Lim HL, Koh LP, Tai BC, Chen Z, Chng WJ, Gopalakrishnan SK, Tan LK.

Hematol Oncol Stem Cell Ther. 2018 Dec;11(4):225-232. doi: 10.1016/j.hemonc.2018.04.001. Epub 2018 Apr 23.

35.

A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase.

Zhou J, Toh SH, Chan ZL, Quah JY, Chooi JY, Tan TZ, Chong PSY, Zeng Q, Chng WJ.

J Hematol Oncol. 2018 Mar 7;11(1):36. doi: 10.1186/s13045-018-0581-9.

36.

Paraprotein interference in the diagnosis of hepatitis C infection.

Ong L, Abid MB, Yip A, Choong C, Chng WJ, de Mel S.

Clin Chem Lab Med. 2018 Jul 26;56(8):e194-e196. doi: 10.1515/cclm-2017-1148. No abstract available.

PMID:
29494337
37.

Identification of novel fusion transcripts in multiple myeloma.

Lin M, Lee PL, Chiu L, Chua C, Ban KHK, Lin AHF, Chan ZL, Chung TH, Yan B, Chng WJ.

J Clin Pathol. 2018 Aug;71(8):708-712. doi: 10.1136/jclinpath-2017-204961. Epub 2018 Feb 16.

PMID:
29453220
38.

Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.

Xiao L, Chen C, Li Z, Zhu S, Tay JC, Zhang X, Zha S, Zeng J, Tan WK, Liu X, Chng WJ, Wang S.

Cytotherapy. 2018 Mar;20(3):420-435. doi: 10.1016/j.jcyt.2017.12.014. Epub 2018 Feb 3.

PMID:
29402645
39.

Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction.

Abid MB, De Mel S, Abid MA, Yap ES, Gopalakrishnan SK, Chen Y, Yuen YC, Wong HC, Lin A, Poon LM, Koh LP, Chng WJ, Tan LK.

Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):174-179. doi: 10.1016/j.clml.2017.12.010. Epub 2018 Jan 5.

PMID:
29398647
40.

Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop.

Tan D, Lee JH, Chen W, Shimizu K, Hou J, Suzuki K, Nawarawong W, Huang SY, Sang Chim C, Kim K, Kumar L, Malhotra P, Chng WJ, Durie B; Asian Myeloma Network.

Leuk Lymphoma. 2018 Oct;59(10):2305-2317. doi: 10.1080/10428194.2018.1427858. Epub 2018 Feb 2. Review.

PMID:
29390932
41.

VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim.

Mustafa N, Ting Lee JX, Adina Nee HF, Bi C, Chung TH, Hart S, Chng WJ.

Oncotarget. 2017 Oct 20;8(60):101847-101864. doi: 10.18632/oncotarget.21988. eCollection 2017 Nov 24.

42.

Tumor-derived exosomes in colorectal cancer progression and their clinical applications.

Zhou J, Li XL, Chen ZR, Chng WJ.

Oncotarget. 2017 Aug 10;8(59):100781-100790. doi: 10.18632/oncotarget.20117. eCollection 2017 Nov 21. Review.

43.

Epigenetic silencing of EVL/miR-342 in multiple myeloma.

Li Z, Wong KY, Chan GC, Chng WJ, Chim CS.

Transl Res. 2018 Feb;192:46-53. doi: 10.1016/j.trsl.2017.11.005. Epub 2017 Nov 23.

PMID:
29242101
44.

CEBPA mutational analysis in acute myeloid leukaemia by a laboratory-developed next-generation sequencing assay.

Ng CWS, Kosmo B, Lee PL, Lee CK, Guo J, Chen Z, Chiu L, Lee HK, Ho S, Zhou J, Lin M, Tan KML, Ban KHK, Tan TW, Chng WJ, Yan B.

J Clin Pathol. 2018 Jun;71(6):522-531. doi: 10.1136/jclinpath-2017-204825. Epub 2017 Nov 27.

PMID:
29180507
45.

Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes.

Ng SB, Chung TH, Kato S, Nakamura S, Takahashi E, Ko YH, Khoury JD, Yin CC, Soong R, Jeyasekharan AD, Hoppe MM, Selvarajan V, Tan SY, Lim ST, Ong CK, Nairismägi ML, Maheshwari P, Choo SN, Fan S, Lee CK, Chuang SS, Chng WJ.

Haematologica. 2018 Feb;103(2):278-287. doi: 10.3324/haematol.2017.180430. Epub 2017 Nov 2.

46.

Neutrophils differentially attenuate immune response to Aspergillus infection through complement receptor 3 and induction of myeloperoxidase.

Goh JG, Ravikumar S, Win MS, Cao Q, Tan AL, Lim JHJ, Leong W, Herbrecht R, Troke PF, Kullberg BJ, Netea MG, Chng WJ, Dan YY, Chai LYA.

Cell Microbiol. 2018 Mar;20(3). doi: 10.1111/cmi.12798. Epub 2017 Dec 20.

PMID:
29088499
47.
48.

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG.

Blood. 2017 Dec 14;130(24):2610-2618. doi: 10.1182/blood-2017-06-791228. Epub 2017 Oct 20.

49.

Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.

Yao L, Mustafa N, Tan EC, Poulsen A, Singh P, Duong-Thi MD, Lee JXT, Ramanujulu PM, Chng WJ, Yen JJY, Ohlson S, Dymock BW.

J Med Chem. 2017 Oct 26;60(20):8336-8357. doi: 10.1021/acs.jmedchem.7b00678. Epub 2017 Oct 10.

PMID:
28953386
50.

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.

Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng WJ, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S, Iskander KS, Dimopoulos MA.

Leuk Lymphoma. 2018 Jun;59(6):1364-1374. doi: 10.1080/10428194.2017.1376743. Epub 2017 Sep 22.

PMID:
28937327

Supplemental Content

Support Center